Insulet | PODD - Current Liabilities


Insulet reported $687.5M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Align Technology USD 1.91B 14.16M Mar/2026
AtriCure USD 73.19M 8.33M Mar/2026
Avanos Medical USD 131.2M 34M Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Boston Scientific USD 4.57B 868M Mar/2026
Cardinal Health USD 41.99B 1.33B Mar/2026
Cooper Companies USD 1.6B 482.9M Dec/2025
Dexcom USD 2.22B 81.3M Mar/2026
Edwards Lifesciences USD 1.41B 404.7M Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Globus Medical USD 482.46M 16.04M Mar/2026
ICU Medical USD 517.9M 19.04M Mar/2026
Inogen USD 64.94M 2.12M Sep/2025
Insulet USD 687.5M 7.4M Mar/2026
Integra LifeSciences USD 346.85M 109.14M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Masimo USD 325.4M 46.2M Mar/2026
Medtronic USD 9.5B 440M Dec/2025
Merit Medical Systems USD 216.87M 22.89M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Solventum Corp USD 3.35B 210M Mar/2026
Stryker USD 6.32B 1.48B Mar/2026
Tandem Diabetes Care USD 247.96M 5.24M Mar/2026
Teleflex USD 728.05M 33.98M Mar/2026
West Pharmaceutical Services USD 674M 19.1M Mar/2026
Zimmer Biomet Holdings USD 2.86B 280.6M Mar/2026